Who We Are
Rare Genetic Epilepsy
Platform
Pipeline
More
Living with Dravet Syndrome
November 28, 2022
Epygenix Therapeutics to Present at the American Epilepsy Society 2022 Annual Meeting in Nashville
April 25, 2017
Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome
June 24, 2019
Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
July 29, 2019
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
January 27, 2020
Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
September 17, 2020
Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
August 02, 2021
Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome
Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome
Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome
August 30, 2021
Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome
February 16, 2022
Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome
March 15, 2022
Epygenix Therapeutics Announces Appointment of Darren Cline as CEO